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Loperamide is an inexpensive, over-the-counter antidiarrheal agent with emerging reports of 
overdose due to its opioid properties. Although it is considered by many patients to be safe, 
cardiotoxicity has been reported, prompting the United States Food and Drug Administration to 
release a warning regarding the arrhythmogenic potential of loperamide. We present a case of a 
32-year-old male presenting in acute loperamide overdose and subsequent cardiac dysrhythmia with 
focal wall motion abnormalities on echocardiogram. This finding has not been previously reported in 
the literature and is unique in this clinical presentation. We also highlight the potential mechanisms 
for loperamide cardiotoxicity and its challenging management. [Clin Pract Cases Emerg Med. 
2019;3(3):262-266.]
INTRODUCTION
Loperamide is an inexpensive, widely used, 
nonprescription antidiarrheal. Its mechanism of action 
involves inhibition of intestinal peristalsis through µ-opioid 
receptor agonism, calcium channel blockade, calmodulin 
inhibition, and by decreasing paracellular permeability.1 
Loperamide is sold under the trade name Imodium in the 
United States (U.S.). When initially introduced in the 1970s, 
loperamide was listed as a Schedule II drug, due to concerns 
over its opioid properties. Loperamide was transferred to 
Schedule V in 1977, and then decontrolled in 1982 following 
multiple volunteer studies showing low risk of dependence at 
therapeutic doses secondary to its poor oral systemic 
bioavailability and limited central nervous system 
penetration.2-4 However, reports of loperamide misuse are 
increasing, more commonly at very high doses of 70-100 
milligrams (mg) per day, either to attenuate the effects of 
opioid withdrawal or for its euphoric effects.5 
As loperamide misuse has become more widespread in the 
past decade, descriptions of significant cardiac dysrhythmias in 
the overdose setting have emerged. These include ventricular 
tachycardia and torsades de pointes secondary to the drug’s 
ability to block cardiac sodium and potassium channels at high 
doses.6-7 The U.S. faces an increasing population of opioid-
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addicted patients with escalating opioid overdose mortality. 
In the setting of efforts to regulate prescription opioid 
medication misuse through new legislation, many patients 
are turning to loperamide as an accessible and inexpensive 
alternative. An added benefit is the lack of social stigma 
associated with its use.8 It is imperative that healthcare 
providers be made aware of this emerging trend of 
loperamide use and its under-recognized cardiac toxicity. 
We describe one case of loperamide overdose presenting 
with cardiac dysrhythmia and focal wall motion 
abnormalities discovered on echocardiogram.
CASE REPORT
A 32-year-old man with a history of polysubstance use 
including heroin was found combative and delirious in his 
room by staff at his sober living facility. Multiple empty 
boxes of loperamide were found in his backpack at the scene 
by emergency medical services. He was given intravenous 
(IV) fluids and transported to the emergency department 
(ED). In the ED, he was notably agitated. On physical exam, 
he was noted to be tachycardic with a regular pulse of 128 
beats per minute and a blood pressure of 123/77 millimeters 
of mercury (mmHg). He was tachypneic with mild 
respiratory distress, diaphoretic, and oriented to person only. 
*
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What do we already know about this clinical 
entity? 
Loperamide is a widely used, nonprescription 
opioid antidiarrheal typically understood to 
have low risk of dependence given its low 
bioavailability and limited central nervous 
system activity.
What makes this presentation of disease 
reportable? 
Prior to this case, there were no reported 
instances of cardiac angiography confirming 
loperamide as a primary pharmacological 
cause of depressed myocardial function.
What is the major learning point? 
Loperamide toxicity can present with elevated 
cardiac injury markers. Resuscitation should 
be guided by treatment of factors that may 
induce electrolyte abnormalities.
How might this improve emergency 
medicine practice? 
This case contributes to awareness of 
the toxidrome as a unique clinical entity. 
Management to guide resuscitation should be 
based on pharmacologic principles.
He was intubated for airway protection using etomidate and 
succinylcholine. An initial electrocardiogram (ECG) showed 
a regular, wide-complex tachycardia with a prolonged QTc 
of 473 milliseconds (ms) and QRS of 140 ms, with an RSR’ 
pattern in lead aVR. This was determined to be sinus 
tachycardia with a left bundle branch block by the consulting 
cardiologist and electrophysiologist (Image 1). The patient’s 
electrolyte levels were within normal limits. 
Acutely, in conjunction with poison control the decision 
was made to manage the patient with 0.4 milligram (mg) IV 
naloxone, 400 mg IV lidocaine, and one gram IV 
magnesium. The patient also received 50 milliequivalent 
(mEq) IV sodium bicarbonate for presumed sodium channel 
toxicity from the high-dose loperamide. An initial troponin I 
was elevated to 0.084 nanograms (ng) per milliliter (mL) 
(reference 0.000-0.045 ng/mL). A point-of-care ultrasound 
(POCUS) demonstrated left ventricular anterior wall 
hypokinesis. He underwent emergent cardiac catheterization, 
which revealed left ventricular anterior wall hypokinesis, 
angiographically normal cardiac arteries with a left ventricle 
ejection fraction (LVEF) of 45%, and an elevated left 
ventricular filling pressure of 23 mmHg. 
During his hospitalization, the patient’s QT peaked one 
day after admission to 616 ms with a QTc 573 ms and a QRS 
of 120 ms (Image 2). At that time the patient admitted to 
taking over 100 mg of loperamide as well as an unknown 
amount of gabapentin as an alternative to opioids on the day 
of admission. His dysrhythmia resolved and QTc normalized 
within four days of admission with no further exposure to 
loperamide. A subsequent transthoracic ECG showed a 
LVEF of 55% and no evidence of diastolic dysfunction or 
hypokinesis of the anterior wall. At discharge, his ECG 
Image 1. Patient’s initial electrocardiogram showing sinus tachycardia with a left bundle branch block and prolonged QT interval of 328 
milliseconds (ms), QTc of 470 ms, and QRS of 140 ms.
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Image 2. Patient’s electrocardiogram one day after admission showing first degree atrioventricular block, and loperamide-induced QT 
prolongation, with a QT interval of 616 milliseconds (ms), QTc of 573 ms, and QRS of 120 ms.
showed a QTc of 442 ms and a QRS of 98 ms (Image 3). A 
loperamide serum concentration was not measured during 
hospitalization. Urine toxicology screen on admission was 
negative for opiates as loperamide is not included in the 
standard panel of drugs screened.
DISCUSSION
This is a novel case of acute loperamide overdose with 
subsequent cardiac dysrhythmia with focal wall motion 
abnormalities on ECG. We do not think gabapentin 
contributed to his cardiac toxicity as the mechanism of 
action, nor would toxicity of gabapentin explain the clinical 
presentation or the laboratory abnormalities. Furthermore, 
there have been no prior reports of arrhythmias with 
gabapentin, although both hypertension and hypotension 
have been reported. The management of loperamide toxicity 
is largely supportive, although some recommendations can 
be extrapolated from case reports, pharmacologic principals, 
and anecdotal experience. In the setting of an acute 
ingestion, loperamide should adsorb to activated charcoal. 
Activated charcoal can be administered within two to four 
hours after a large overdose, provided the patient is not an 
aspiration risk, in contrast to our case.9 
For patients with decreased responsiveness or 
respiratory depression, naloxone can be considered as an 
adjunct to appropriate airway management. This modality 
showed benefit in one adult case10 and a series of pediatric 
cases.11,12 In one pediatric case, a four-month-old girl 
inadvertently ingested approximately two mg/kg of 
loperamide liquid and subsequently became comatose with 
respiratory depression. She recovered after three injections 
of 0.01 mg IV naloxone over 24 hours.12 While naloxone 
should reverse the respiratory depression induced by 
loperamide’s µ-opioid agonism, it would not be expected to 
affect the cardiotoxicity associated with loperamide. However, 
little data exists to guide naloxone use in acute loperamide 
toxicity, including dosing. Given loperamide’s long half-life, 
repeated doses of naloxone may be warranted.12 
ECG abnormalities are characteristic of loperamide 
toxicity, particularly prolonged QT and QRS intervals. 
Again, little data exists to guide cardiac resuscitation in the 
setting of loperamide ingestion. It is therefore reasonable to 
treat factors that may induce ECG interval prolongation 
such as electrolyte abnormalities and other medications. 
This may be attempted with antiarrhythmic medications 
such as amiodarone, sotalol, lidocaine, or procainamide,13-15 
as well as sodium bicarbonate to overcome loperamide’s 
sodium channel blockade. Class 1b antiarrhythmic agents 
such as lidocaine may be preferable in loperamide toxicity 
as they have weak sodium channel blocking effects and 
decrease the effective refractory period in comparison to 
other class one agents.
CONCLUSION
Within the literature, the majority of case reports 
regarding loperamide overdose describe a constellation of 
symptoms including decreased levels of consciousness, 
unheralded syncope, markedly increased QTc and QRS 
intervals, and dysrhythmias including ventricular 
tachycardia and torsades de pointes. Only one case is 
reported in which a long-time loperamide user presented 
with severely depressed global left ventricular function 
measured by ECG but normal coronary angiography.16 
Additionally, two case reports of loperamide overdose 
described mild global hypokinesis of the left ventricle as 
measured by ECG without corresponding coronary 
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Image 3. Patient’s electrocardiogram upon discharge, showing a sinus rhythm with a QT interval of 434 milliseconds (ms), QTc of 442 
ms, and QRS of 98 ms.
angiography.15,17 The literature includes only one case 
report of acute loperamide overdose involving a patient 
who received both an ECG and coronary angiography. In 
that case, investigations revealed normal ventricular 
function and no angiographic abnormalities.18 This case 
provides an opportunity to describe a novel presentation of 
acute loperamide toxicity, with an elevated cardiac injury 
marker and confirmed focal left ventricular anterior wall 
hypokinesis that subsequently resolved after clearance of 
the drug. 
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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